Cascadian Therapeutics Announces 2018 Outlook and Recent Progress
04 janv. 2018 08h30 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for tucatinib, an...